Project Grant R01CA308325
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $724K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Syracuse, NY 13210, USA
Similar Awards
- The National Cancer Institute awarded The Johns Hopkins University $218,089 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and test engineered natural killer cell therapy targeting acute myeloid leukemia. The funded work develops chimeric cytokine receptor (CCR)-engineered NK cells designed to attack AML-associated surface antigens and overcome AML-mediated NK cell suppression. In Aim 1, the recipient will engineer NK cells to express dual interleukin...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded Albert Einstein College of Medicine $431,970 under the Cancer Treatment Research program (CFDA 93.395) on April 1, 2026, to investigate combination approaches to acute myeloid leukemia targeting both CD123-directed NK cell engagers and BCL-2 inhibition through venetoclax. The research will employ dynamic BH3 profiling to probe mitochondrial priming mechanisms and test whether...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $671,252 on July 1, 2026, under Cancer Biology Research (CFDA 93.396) to investigate CD4 T cell and dendritic cell interactions that license CD8 T cell cytotoxicity against tumor cells. The research examines how tumor-specific CD4 T cells, CD8 T cells, and dendritic cells form three-cell clusters (triads) within tumors to overcome CD8 T cell dysfunction and exhaustion. Prior work by the recipient demonstrated...
- The National Cancer Institute, within the Department of Health and Human Services, awarded $442,146 to The University of Texas MD Anderson Cancer Center on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct a first-in-class clinical trial of natural killer cell therapy engineered to target intracellular antigens in acute myeloid leukemia and high-risk myelodysplastic syndromes. The funded work develops and tests cord blood-derived, off-the-shelf NK cells...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded $1.964 million to Cleveland Clinic Lerner College of Medicine of Case Western Reserve University on September 22, 2025, under the Cancer Biology Research program (CFDA 93.396) to investigate the role of VISTA in driving immune evasion in acute myeloid leukemia. The research addresses an unmet clinical need in AML treatment. While immune checkpoint receptor blockade has revolutionized therapy for solid...
- The National Cancer Institute awarded the University of California Irvine $586,364 on April 7, 2026, for a Project Grant (R01CA308352) under the Cancer Biology Research program (CFDA 93.396). The research investigates Group 1 innate lymphoid cells (ILCs), particularly ILC1s, as a potential therapeutic approach to acute myeloid leukemia (AML). Prior work published by the recipient in Nature Immunology demonstrated that ILC1s from healthy donors induce the death of leukemia stem cells and block...
- The National Institutes of Health National Cancer Institute awarded The University of Texas Southwestern Medical Center $688,012 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop novel RPS23 inhibitors for the treatment of acute myeloid leukemia. The funded research develops ligands that bind the ribosomal protein RPS23 and activate the integrated stress response through the GCN2 kinase pathway, triggering apoptosis in leukemia cells. The investigator-led...
- The National Cancer Institute awarded New York University $716,681 on May 22, 2026, under the Cancer Biology Research program (CFDA 93.396) to fund research into understanding and therapeutically targeting myeloid sarcoma, an extramedullary subtype of acute myeloid leukemia characterized by solid tumor-like invasive masses at multiple anatomical sites and dismal survival outcomes below 20% at five years. The funded research builds on the recipient's prior transcriptomic, genomic, and spatial...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded the University of Rochester $624,494 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate combined stereotactic body radiotherapy and interleukin-12 messenger RNA nanotechnology as a treatment strategy for pancreatic ductal adenocarcinoma. The research targets T cell dynamics in the pancreatic cancer tumor microenvironment by combining localized stereotactic body...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $415,259 to the Rector & Visitors of the University of Virginia to conduct research on the role of long noncoding RNAs in acute myeloid leukemia (AML). The project aims to 1) determine the role of a specific regulatory RNA in primary and relapsed AML, and 2) define the mechanism underlying its deregulation in AML. This research will provide insights into how noncoding RNAs...